ACP
SURF

Acuta Capital Partners’s Surface Oncology, Inc. Common Stock SURF Stock Holding History

Acuta Capital Partners’s Portfolio SURF Stock Details SURF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-999,500
Closed -$9.23M – 60
2020
Q4 		$9.23M Sell
999,500
-88,500
-8% -$769K 2.51% 16
2020
Q3 		$7.51M Buy
1,088,000
+863,000
+384% +$5.24M 2.04% 19
2020
Q2 		$1.48M Buy
+225,000
New +$812K 0.43% 43

Other funds holding SURF

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acuta Capital Partners's SURF Position: Q1 2021 in Review

Acuta Capital Partners sold out of Surface Oncology, Inc. Common Stock (SURF) in Q1 2021, closing a stake of 999,500 shares — an estimated $9.23M sold.

Acuta Capital Partners first reported a position in SURF in Q2 2020 and held it in 3 quarters. The position peaked at $9.23M in Q4 2020. 90 funds tracked by Wall St. Rank hold SURF as of Q1 2021.

  • Acuta Capital Partners reported no remaining Surface Oncology, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Acuta Capital Partners sold 999,500 Surface Oncology, Inc. Common Stock shares in Q1 2021, an estimated $9.23M.
  • Acuta Capital Partners first reported a position in Surface Oncology, Inc. Common Stock in Q2 2020 and held it in 3 quarters.
  • Acuta Capital Partners's Surface Oncology, Inc. Common Stock position peaked at $9.23M in Q4 2020.
  • 90 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q1 2021.

Based on Acuta Capital Partners's 13F filing for Q1 2021, filed 17 May 2021.